industry session programmes

1

30th EADV Congress – Industry Sessions Agenda

INDUSTRY SESSION PROGRAMMES

2


TABLE OF CONTENTS

INDUSTRY SESSION PROGRAMMES .................................................................................................................... 1

VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE ....................................................................... 6

Satellite Symposia .................................................................................................................................... 6

Wednesday 29 September 2021 .......................................................................................................................... 6



Thursday 30 September 2021 .............................................................................................................................. 7



Friday 01 October 2021 ........................................................................................................................................ 8



Saturday 02 October 2021 .................................................................................................................................... 9

VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE ......................................................................10

Industry HUB ..........................................................................................................................................10

INDUSTRY SESSION PROGRAMME AND FACULTY IN PARTICULAR .............................................................11

ACCESS TO INDUSTRY SESSIONS AND REGULATIONS RELATED TO INDUSTRY ACTIVITIES ...........................11

3


SATELLITE SYMPOSIA – Wednesday 29 September 2021

SAT 10 - Vichy Laboratoires ................................................................................................................................ 12

SAT 23 - Eucerin by BEIERSDORF ........................................................................................................................ 13

SAT 24 - Bella Aurora Labs .................................................................................................................................. 13

SAT 25 - Amryt Pharma DAC ............................................................................................................................... 14

SAT 36 - Novartis ................................................................................................................................................ 14

SAT 37 - Janssen ................................................................................................................................................. 15

SAT 38 - L'Oréal - La Roche-Posay ...................................................................................................................... 16

SAT 39 - Sanofi Genzyme & Regeneron .............................................................................................................. 17

SAT 40 - Lilly ........................................................................................................................................................ 17

SAT 41 - CeraVe .................................................................................................................................................. 18

SAT 42 - Bristol Myers Squibb............................................................................................................................. 18

SAT 44 - Amgen................................................................................................................................................... 19



SAT 59 - Medscape – Supported by an independent educational grant from Janssen Immunology ................ 22

SATELLITE SYMPOSIA – Thursday 30 September 2021

SAT 61 - Galderma .............................................................................................................................................. 23

SAT 62 - Almirall.................................................................................................................................................. 23

SAT 63 - Incyte Biosciences International Sàrl .................................................................................................... 24

SAT 64 - Medscape – Supported by an independent educational grant from Lilly. ........................................... 24

SAT 74 - Lilly ........................................................................................................................................................ 25


SAT 76 - AbbVie .................................................................................................................................................. 26

SAT 77 - Medscape – Supported by an independent educational grant from UCB. .......................................... 26

SAT 78 - Pfizer ..................................................................................................................................................... 27

SAT 79 - LEO Pharma .......................................................................................................................................... 27

SAT 80 - Galderma .............................................................................................................................................. 28

SAT 82 - Bristol Myers Squibb............................................................................................................................. 28

SAT 83 - Developed by Medthority. Supported by educational sponsorship from Novartis ............................. 29

SAT 84 - AbbVie .................................................................................................................................................. 29

4


SAT 85 - Sanofi Genzyme .................................................................................................................................... 30

SAT 86 - Med Learning Group on behalf of Regeneron Pharmaceuticals, Inc and Sanofi Genzyme ................. 30

SAT 87 - Janssen ................................................................................................................................................. 31

SAT 88 - Galderma .............................................................................................................................................. 31

SAT 89 - Almirall.................................................................................................................................................. 32

INDUSTRY HUB – Thursday 30 September 2021

HUB 1.03 - L'Oréal Paris ...................................................................................................................................... 33

HUB 1.04 - Amgen .............................................................................................................................................. 33

HUB 1.05 - Sofwave ............................................................................................................................................ 34

HUB 1.06 - L'Oréal - La Roche-Posay .................................................................................................................. 34

HUB 1.07 - CeraVe .............................................................................................................................................. 35

HUB 2.01 - Galderma .......................................................................................................................................... 35

HUB 2.02 - PIERRE FABRE DERMATOLOGIE ........................................................................................................ 36

HUB 2.03 - LEO Pharma ...................................................................................................................................... 36

HUB 2.04 - UCB ................................................................................................................................................... 37

HUB 2.05 - Almirall ............................................................................................................................................. 38

HUB 2.06 - Janssen ............................................................................................................................................. 39

HUB 2.07 - UCB ................................................................................................................................................... 39

SATELLITE SYMPOSIA – Friday 01 October 2021

SAT 95 - Galderma .............................................................................................................................................. 40

SAT 108 - Novartis .............................................................................................................................................. 40

SAT 109 - AbbVie ................................................................................................................................................ 41

SAT 110 - Sanofi Genzyme & Regeneron ............................................................................................................ 41

SAT 111 - UCB ..................................................................................................................................................... 42

SAT 112 - Pfizer ................................................................................................................................................... 42

SAT 113 - Galderma ............................................................................................................................................ 43

SAT 114 - Almirall ............................................................................................................................................... 43

SAT 115 - LABORATOIRES DERMATOLOGIQUES AVENE ..................................................................................... 44

SAT 117 - AbbVie ................................................................................................................................................ 45

SAT 118 - Sanofi Genzyme & Regeneron ............................................................................................................ 46

SAT 119 - Janssen ............................................................................................................................................... 46

SAT 120 - Galderma ............................................................................................................................................ 47

5


SAT 121 - Boehringer Ingelheim International GmbH ........................................................................................ 47

INDUSTRY HUB – Friday 01 October 2021

HUB 1.08 - L'Oréal - La Roche-Posay .................................................................................................................. 48

HUB 1.09 - siHealth ............................................................................................................................................. 48

HUB 1.11 - Vichy Laboratoires ............................................................................................................................ 49

HUB 1.12 - Pfizer ................................................................................................................................................. 49

HUB 1.13 - CeraVe .............................................................................................................................................. 50

HUB 2.08 - Galderma .......................................................................................................................................... 51

HUB 2.10 - LEO Pharma ...................................................................................................................................... 51

HUB 2.11 - Janssen ............................................................................................................................................. 52

HUB 2.12 - LEO Pharma ...................................................................................................................................... 53

HUB 2.13 - LEO Pharma ...................................................................................................................................... 54

HUB 2.14 - UCB ................................................................................................................................................... 54

SATELLITE SYMPOSIA – Saturday 02 October 2021

SAT 151 - Boehringer Ingelheim International GmbH ........................................................................................ 55

INDUSTRY HUB – Saturday 02 October 2021

HUB 2.16 - UCB ................................................................................................................................................... 56

HUB 2.18 - Galderma .......................................................................................................................................... 56

HUB 2.19 - LEO Pharma ...................................................................................................................................... 57

6


VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE

Satellite Symposia

Wednesday 29 September 2021

Access restricted to Health Care Professionals Only Access Open to All

Room name Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13

Capacity Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited


Morning Slots 1 Session Code SAT10

10:00-11:00 Presentation: 10:00-11:00 Vichy

Laboratoires

Morning Slots 2 Session Code SAT23 SAT24 SAT25

11:30-12:30 Presentation: 11:30-12:30 Eucerin by

BEIERSDORF Bella Aurora

Labs Amryt Pharma

DAC

Lunch Slots Session Code SAT36 SAT37 SAT38 SAT39

13:00-14:00 Presentation: 13:00-14:00 Novartis Janssen L'Oréal - La

Roche-Posay Sanofi Genzyme

& Regeneron

Afternoon Slots 1 Session Code SAT40 SAT41 SAT42

14:30-15:30 Presentation: 14:30-15:30 Lilly CeraVe Bristol Myers

Squibb

Afternoon Slots 2 Session Code SAT44

15:45-16:45 Presentation: 15:45-16:45 Amgen

Evening Slots Session Code SAT57 SAT59 SAT51

17:00-18:30

Presentation: 17:00-18:00 Sanofi Genzyme

& Regeneron

Medscape – Supported by

Janssen Immunology

Sanofi Genzyme &

Regeneron

Extended Presentation:

17:00-18:30

7



Satellite Symposia

Thursday 30 September 2021





Morning Slots Session Code SAT61 SAT62 SAT63 SAT64

08:30-09:30 Presentation: 08:30-09:30 Galderma Almirall

Incyte Biosciences

International Sàrl


an independent educational

grant from Lilly.

Lunch Slots Session Code SAT74 SAT75 SAT76 SAT77 SAT78 SAT79 SAT80 SAT82

13:00-14:00 Presentation: 13:00-14:00 Lilly Sanofi Genzyme &

Regeneron AbbVie


an independent educational

grant from UCB

Pfizer LEO Pharma Galderma Bristol Myers

Squibb

Evening Slots Session Code SAT83 SAT84 SAT85 SAT86 SAT87 SAT88 SAT89

18:00-19:30

Presentation: 18:00-19:00

Developed by Medthority.

Supported by educational

sponsorship from Novartis

AbbVie Sanofi Genzyme

Med Learning Group on behalf

of Regeneron Pharmaceuticals,

Inc and Sanofi Genzyme

Janssen Galderma Almirall

Extended Presentation: 19:00-19:30

8



Satellite Symposia

Friday 01 October 2021





Morning Slots Session Code SAT95

08:30-09:30 Presentation: 08:30-09:30 Galderma

Lunch Slots Session Code SAT108 SAT109 SAT110 SAT111 SAT112 SAT113 SAT114 SAT115

13:00-14:00 Presentation: 13:00-14:00 Novartis AbbVie Sanofi

Genzyme & Regeneron

UCB Pfizer Galderma Almirall LABORATOIRES

DERMATOLOGIQUES AVENE

Evening Slots Session Code SAT117 SAT118 SAT119 SAT120 SAT121

18:00-19:30


AbbVie Sanofi

Genzyme & Regeneron

Janssen Galderma

Boehringer Ingelheim

International GmbH


9



Satellite Symposia

Saturday 02 October 2021





Morning Slots 1 Session Code

08:30-09:30 Presentation: 08:30-09:30

Lunch Slots Session Code

13:00-14:00 Presentation: 13:00-14:00

Evening Slots Session Code SAT151

18:00-19:30


Boehringer Ingelheim

International GmbH


10



Industry HUB


Thursday 30 September 2021 Friday 01 October 2021 Saturday 02 October 2021

Room Names Room HUB 1 Room HUB 2 Location Room HUB 1 Room HUB 2 Location Room HUB 1 Room HUB 2

Capacities 100 pax 200 pax Capacity 100 pax 200 pax Capacity 100 pax 200 pax

Session Code HUB2.01 Session Code HUB1.08 HUB2.08 Session Code


Galderma Presentation: 09:00-09:45 L'Oréal - La Roche-Posay Galderma Presentation: 09:00-09:45

Session Code HUB2.02 Session Code HUB1.09 Session Code HUB2.16

Presentation: 10:00-10:45 PIERRE FABRE

DERMATOLOGIE Presentation: 10:00-10:45 siHealth Presentation: 10:00-10:45 UCB

Session Code HUB1.03 HUB2.03 Session Code HUB2.10 Session Code

Presentation: 11:15-12:00 L'Oréal Paris LEO Pharma Presentation: 11:15-12:00 LEO Pharma Presentation: 11:15-12:00

Session Code HUB1.04 HUB2.04 Session Code HUB1.11 HUB2.11 Session Code HUB2.18

Presentation: 12:15-13:00 Amgen UCB Presentation: 12:15-13:00 Vichy Laboratoires Janssen Presentation: 12:15-13:00 Galderma

13:00 - 14:00 break

Session Code HUB1.05 HUB2.05 Session Code HUB1.12 HUB2.12 Session Code HUB2.19

Presentation: 14:00-14:45 Sofwave Almirall Presentation: 14:00-14:45 Pfizer LEO Pharma Presentation: 14:00-14:45 LEO Pharma

Session Code HUB1.06 HUB2.06 Session Code HUB1.13 HUB2.13 Session Code

Presentation: 15:00-15:45 L'Oréal - La Roche-Posay Janssen Presentation: 15:00-15:45 CeraVe LEO Pharma Presentation: 15:00-15:45

Session Code HUB1.07 HUB2.07 Session Code HUB1.14 HUB2.14 Session Code

Presentation: 16:00-16:45 CeraVe UCB Presentation: 16:00-16:45 UCB Presentation: 16:00-16:45

11


INDUSTRY SESSION PROGRAMME AND FACULTY IN PARTICULAR

The Industry session organiser is solely responsible for keeping any of its industry sessions activities compliant with all

relevant laws and regulations. EADV is not involved with or has any control over the content, quality, organisation,

operation, scientific integrity of the activity and materials provided by the industries. EADV is not involved in the

selection of speakers, moderators and other faculty.

ACCESS TO INDUSTRY SESSIONS AND REGULATIONS RELATED TO INDUSTRY ACTIVITIES

As a multidisciplinary audience will be attending the EADV 30th Congress, please make sure to select the right

category, Healthcare Professionals (HCPs) and Non-Healthcare Professionals (NON-HCPs), during the registration

process.

Access to any industry sessions where data or research of prescription medicines is presented will be limited exclusively to Healthcare Professionals (HCPs) only. For more information please download the Austrian Ethical Rules.

Industry Session organisers may limit participation to certain representative groups independently from EADV

recommendations if deemed imperative to the achievement of the intended purpose of the Industry session.

https://drive.google.com/file/d/1GXhlXuhnAufB5dklumAWT4TjwNxij91q/view

12



SATELLITE SYMPOSIA

SAT 10 Vichy Laboratoires (Open to all)

Stressed skin: from acute exposome impact to skin care innovation

10:00 - 11:00 Room: 1

Chair: Thierry Passeron (Nice, France)

SAT 10.01 10:00 A new rising concern among patients: stressed skin

Thierry Passeron (Nice, France)

SAT 10.02 10:07 Probiotic fractions, 25 years of research and proven efficacy in

restoring and regenerating the skin barrier and skin

immunological-antioxidant defenses

Frédérique Labatut (Chevilly la rue, France)

SAT 10.03 10:12 Skin stressed by UV and pollution: can we prevent it?

Giuseppe Valacchi (Ferrara, Italy)

SAT 10.04 10:22 Probiotic fractions proven efficacy in the following dermatological

indications:

-Adjuvant to topical retinoids for skin ageing

Jerry Tan (Ontario, Canada)

-Rosacea clinical signs and symptoms

Enzo Berardesca (Milano, Italy)

-Facial COVID-19 mask dermatitis

Markus Reinholz (München, Germany)

SAT 10.05 10:42 Conclusion


SAT 10.06 10:47 Q&A


13



SATELLITE SYMPOSIA

SAT 23 Eucerin by BEIERSDORF (HCP only)

Acne leaves its marks: Spot the problem – Face the challenge

11:30 - 12:30 Room: 1

Chair: Shirin Keyhanian (Hamburg, Germany)

SAT 23.01 11:30 Introduction

Shirin Keyhanian (Hamburg, Germany)

SAT 23.02 11:35 Acne and acne-related post-inflammatory hyperpigmentation –

quo vadis?

Vincenzo Bettoli (Ferrara, Italy)

SAT 23.03 11:50 Acne and acne-related post-inflammatory hyperpigmentation – a

physical and emotional burden

Alison Layton (Harrogate, United Kingdom)

SAT 23.04 12:05 Maximizing the power of patented Thiamidol with innovation

tailored for acne-prone skin: Reduction & prevention of blemishes

and post-acne marks for improved quality of life

Julia Gallinger (Hamburg, Germany)

SAT 23.05 12:20 Discussion, Q & A

All – panel discussion

SAT 24 Bella Aurora Labs (HCP only)

MIA-inhibitors technology: a new option in managing vitiligo

11:30 - 12:30 Room: 2

Chair: Agustín Alomar Muntañola (Barcelona, Spain)

SAT 24.01 11:30 Vitiligo: pathogenesis and current treatment options.

Agustín Alomar Muntañola (Barcelona, Spain)

SAT 24.02 11:50 The role of MIA protein in the pathogenesis of vitiligo and clinical

efficacy of the MIA inhibitor technology.

Matteo Bordignon (Padova, Italy)

SAT 24.03 12:20 A new development in vitiligo

Marta Bajona Roig (Santa Coloma de Cervelló, Spain)

SAT 24.04 12:25 Round Table and Q&A

Marta Bajona Roig (Santa Coloma de Cervelló, Spain)

14



SATELLITE SYMPOSIA

SAT 25 Amryt Pharma DAC (Open to all)

Epidermolysis Bullosa: The Depth of Disease and Improving Patient

Outcomes

11:30 - 12:30 Room: 3

Chair: Eli Sprecher (Tel Aviv, Israel)


Eli Sprecher (Tel Aviv, Israel)

SAT 25.02 11:35 The visible challenge and natural history

Danielle Greenblatt (London, United Kingdom)

SAT 25.03 11:50 Inflammation and pathophysiology: What lies beneath

Leena Bruckner-Tuderman (Freiburg, Germany)

SAT 25.04 12:05 Improving outcomes for patients: Future developments


SAT 25.05 12:20 Panel discussion


Leena Bruckner-Tuderman (Freiburg, Germany)

Danielle Greenblatt (London, United Kingdom)

SAT 25.06 12:30 Summary and close


SAT 36 Novartis (HCP only)

The complete management of psoriatic disease in a COVID world

13:00 - 14:00 Room: 1

Chair: Diamant Thaçi (Luebeck, Germany)


Diamant Thaçi (Luebeck, Germany)

SAT 36.02 13:05 What really matters to the patient?

April Armstrong (Los Angeles, CA, United States)

SAT 36.03 13:15 Thinking beyond the skin in psoriatic disease


SAT 36.04 13:30 Safety matters: making informed treatment decisions in a post-

pandemic world

Christopher Griffiths (Manchester, United Kingdom)

SAT 36.05 13:40 Live Panel discussion and Q&A


SAT 36.06 13:55 Closing remarks


15



SATELLITE SYMPOSIA

SAT 37 Janssen (HCP only)

Diving deep: harnessing the potential of the IL-23 pathway

13:00 - 14:00 Room: 2

Chairs: Jo Lambert (Ghent, Belgium) Bruce Strober (New Haven, United States)

SAT 37.01 13:00 Welcome and introduction

Jo Lambert (Ghent, Belgium)

SAT 37.02 13:05 Perspectives from dermatology: the potential of IL-23 inhibition for

long-term disease remission

Bruce Strober (New Haven, United States)

SAT 37.03 13:20 Perspectives from rheumatology: going under and beyond the skin

Daniel Aletaha (Vienna, Austria)

SAT 37.04 13:35 Putting the pieces together: looking for best value in psoriasis


SAT 37.04 13:50 Panel discussion and Q&A



Daniel Aletaha (Vienna, Austria)

SAT 37.06 13:55 Closing remarks


16



SATELLITE SYMPOSIA

SAT 38 L'Oréal - La Roche-Posay (Open to all)

REVOLUTION IN PHOTOPROTECTION:

▪ How to recommend and adapt photoprotection according to

skin phototype and dermatoses?

▪ Innovation on UVA: launching a new filter

13:00 - 14:00 Room: 3

Chair: Thierry Passeron (Nice, France)



SAT 38.02 13:05 Skin phototypes

Sergio Schalka (Sao Paulo, Brazil)

SAT 38.03 13:10 Photoaging

Jean Krutmann (Düsseldorf, Germany)

SAT 38.04 13:15 Skin cancers

Brigitte Dréno (Nantes, France)

SAT 38.05 13:20 Photodermatoses

Henry Lim (Detroit, United States)

SAT 38.06 13:25 Pigmentary disorders


SAT 38.07 13:30 Skin inflammatory disorders

Jorge Ocampo Candiani (Monterrey, Mexico)

SAT 38.08 13:35 Going further on uva: an even more complete protection

Martin Josso (Paris, France)

SAT 38.09 13:50 Q&A


17



SATELLITE SYMPOSIA

SAT 39 Sanofi Genzyme & Regeneron (Open to all)

How Multidisciplinary Teams Improve Communication and Care in

the Management of Atopic Dermatitis: Findings from the Atopic

Dermatitis Quality of Care Initiative

13:00 - 14:00 Room: 4

Chair: Eric Simpson (Portland, United States)

SAT 39.01 13:00 Overview of Multidisciplanary Teams in the Atopic Dermatitis

Quality of Care Initiative

Eric Simpson (Portland, United States)

SAT 39.02 13:10 Outcomes of cross-specialty collaboration in treatment of AD:

Patients

Ketty Peris (Rome, Italy)

SAT 39.03 13:25 Outcomes of cross-specialty collaboration in treatment of AD: HCPs

Marjolein de Bruin-Weller (Utrecht, Netherlands)

SAT 39.04 13:40 Multidisciplinary Teams: Case Studies from International Centers


SAT 39.05 13:55 Discussion and Final Questions


Ketty Peris (Rome, Italy)


SAT 40 Lilly (HCP only)

Bringing Clinical Trial Data To Life- 1 Year Of

Olumiant (Baricitinib) Experience in Atopic Dermatitis Clinical

Practice

14:30 - 15:30 Room: 10

Chair: Thomas Bieber (Bonn, Germany)


Thomas Bieber (Bonn, Germany)

SAT 40.02 14:45 Translating clincal trial data into clinical practice


SAT 40.03 15:00 Flexible patient- happy patient, what matters during long term

management

Audrey Nosbaum (Lyon, France)

SAT 40.04 15:15 Lessons learnt from Rheumatology

Torsten Witte (Hannover, Germany)

SAT 40.05 15:25 Q&A session


SAT 40.06 15:35 Wrap-up


18



SATELLITE SYMPOSIA

SAT 41 CeraVe (Open to all)

Addressing Acne Medication-Induced Barrier Dysfunction with

Adjunctive Therapy

14:30 - 15:30 Room: 11

Chair: Dr. Zoe Draelos (High Point, United States) Prof. Brigitte Dreno (Nantes, France)

SAT 41.01 14:30 Addressing Acne Medication-Induced Barrier Dysfunction with

Adjunctive Therapy

Dr. Zoe Draelos (High Point, United States) Prof. Brigitte Dreno (Nantes, France)

SAT 41.02 15:15 Live Q&A

Dr. Zoe Draelos (High Point, United States)

Prof. Brigitte Dreno (Nantes, France)

SAT 42 Bristol Myers Squibb (HCP only, no industry participants)

The TYK/JAK Family and Psoriasis Pathology

14:30 - 15:30 Room: 12

Chair: Jo Lambert (Ghent, Belgium)

SAT 42.01 14:30 A Molecular View of the Pathophysiology of Psoriasis


SAT 42.02 14:50 Differentiating TYK/JAK Family Members

Andrew Alexis (New York, United States)

SAT 42.03 15:10 Clinical Data for TYK2 and JAK1,2,3 Inhibitors in Psoriasis

Matthias Augustin (Hamburg, Germany)

19



SATELLITE SYMPOSIA

SAT 44 Amgen (HCP only)

Telemedicine, treatment, and evidence: How can we provide the

best treatment for patients with moderate psoriasis?

15:45 - 16:45 Room: 10

Chair: Matthias Augustin (Hamburg, Germany)



SAT 44.02 15:55 What are the unique needs and perspectives of patients with

moderate psoriasis?

Kave Shams (Leeds, United Kingdom)

SAT 44.03 16:05 How could telemedicine improve the patient experience in

moderate psoriasis?

Alexander Zink (Munich, Germany)

SAT 44.04 16:15 How can specific manifestations of PsO affect patient QoL?

Kave Shams (Leeds, United Kingdom)

SAT 44.05 16:25 How can RWE complement clinical trial data when selecting the

most appropriate treatment for patients with moderate Pso?


SAT 44.06 16:35 Panel discussion with live Q&A


SAT 44.07 16:40 Summary and close: What is the future for PsO?


20



SATELLITE SYMPOSIA


Addressing the full impact of AD through the perspectives of kids

and teens, caregivers and physicians: Key findings from the AD-GAP

survey

17:00-18:30 Room: 4

Chair: Korey Capozza (Santa Barbara, United States)

SAT 51.01 17:00 More than skin deep: Introducing the AD-GAP survey

Korey Capozza (Santa Barbara, United States)

SAT 51.02 17:10 Addressing the full impact of AD

Amy Paller (Chicago, United States)

SAT 51.03 17:25 Living in the now with AD: Panel Discussion



Stephan Weidinger (Kiel, Germany)

Mark Tang (Singapore, Singapore)

Andrew Pink (London, United Kingdom)

SAT 51.04 18:10 Q&A




Mark Tang (Singapore, Singapore)

Andrew Pink (London, United Kingdom)

SAT 51.05 18:25 Meeting Close


21



SATELLITE SYMPOSIA

SAT 57 Sanofi Genzyme & Regeneron (HCP only)

Clinical Importance of Type 2 Inflammation in Dermatoses and

Challenges in the Management of Atopic Dermatitis in the

Pandemic Era

17:00 - 18:00 Room: 1

Chair: Emma Guttman-Yassky (New York, United States)


Emma Guttman-Yassky (New York, United States)

SAT 57.02 17:02 Type 2 Inflammation in Atopic Dermatitis and Other Dermatologic

Diseases

Patrick Brunner (New York, United States)

SAT 57.03 17:12 Systemic Therapy in Patients with Atopic Dermatitis

April Armstrong (Los Angeles, United States)

SAT 57.04 17:27 Impact of COVID-19 on the Assessment and Treatment of Atopic

Dermatitis


SAT 57.05 17:47 Live Q&A with audience


22



SATELLITE SYMPOSIA

SAT 59 Medscape – Supported by an independent educational grant from

Janssen Immunology (HCP only)

Exploring New Frontiers in Atopic Dermatitis

17:00 - 18:30 Room: 3

Chair: Emma Guttman-Yassky (New York, United States)

SAT 59.01 17:00 Unmet needs in atopic dermatitis

Kilian Eyerich (Munich, Germany)

SAT 59.02 17:10 AD pathophysiology and role of IL-1α in AD


SAT 59.03 17:25 Overview of therapeutic targets in AD

Alan Irvine (Dublin, Ireland)

SAT 59.05 17:40 IL-1α in other dermatologic conditions

Errol Prens (Rotterdam, the Netherlands)

SAT 59.06 17:50 Panel Discussion


23



SATELLITE SYMPOSIA

SAT 61 Galderma (Open to all)

Paediatric Atopic Dermatitis: Current Developments

08:30 - 09:30 Room: 1

Chair: Krzysztof Piotrowski (Vevey, Switzerland)

SAT 61.01 08:30 Paediatric Dermatitis – what’s new in 2021?

Adelaide Hebert (Houston, United States)

SAT 61.02 08:50 Is it possible to prevent atopic dermatitis? Randomized control

study of high risk babies

Mark Koh (Singapore, Singapore)

SAT 61.03 09:05 Multidisciplinary management of children with atopic dermatitis,

including psychological treatment

Mark Koh (Singapore, Singapore)

SAT 61.04 09:20 Q&A

Krzysztof Piotrowski (Vevey, Switzerland)

SAT 62 Almirall (HCP only)

Tailoring topical psoriasis treatments to patients' needs and

expectations

08:30 - 09:30 Room: 2

Chair: Peter Van de Kerkhof (Nijmegen, Netherlands)

SAT 62.01 08:30 Tailoring topical psoriasis treatments to patients’ needs and

expectations. Welcome and introductions.

Peter Van de Kerkhof (Nijmegen, Netherlands)

SAT 62.02 08:40 The role of topical therapies along the psoriasis patient journey

Andreas Pinter (Frankfurt am Main, Germany)

SAT 62.03 08:55 Engaging psoriasis patients in adherence (and outcomes) to topical

treatments

Anthony Bewley (London, United Kingdom)

SAT 62.04 09:10 Questions and answers discussion


24



SATELLITE SYMPOSIA

SAT 63 Incyte Biosciences International Sàrl (Open to all)

Looking through the lens: an emerging future for vitiligo patients.

08:30 - 09:30 Room: 3

Chair: Khaled Ezzedine (Paris, France)

SAT 63.01 08:30 Welcome and introductions

Khaled Ezzedine (Paris, France)

SAT 63.02 08:34 The disease mechanisms driving vitiligo

Mauro Picardo (Rome, Italy)

SAT 63.03 08:52 The unmet needs of patients with vitiligo; how should they be

measured?

Nanja van Geel (Heusden, Belgium)

SAT 63.04 09:10 Current and future clinical research in vitiligo


SAT 63.05 09:28 Concluding remarks and meeting close



Lilly. (HCP only)

The Clinical challenges of Hair Disorders: What You Need To Know.

08:30-09:30 Room: 4

Chair: Brett King (New Haven, United States)

SAT 64.01 08:30 Welcome and Introductions

Brett King (New Haven, United States)

SAT 64.02 08:31 The Impact of Hair Disorders: Understanding a Patient’s Journey

Antonella Tosti (Miami, United States)

SAT 64.03 08:50 Diagnosis and Assessment of Hair Disorders

Lidia Rudnicka (Warsaw, Poland)

SAT 64.04 09:05 The Immunopathogenesis and Management of Hair Disorders

Brett King (New Haven, United States)

SAT 64.05 09:20 Q&A


25



SATELLITE SYMPOSIA

SAT 74 Lilly (HCP only)

What new data tell us – a fresh look into Nail Psoriasis

management

13:00 - 14:00 Room: 1

Chair: Alexander Egeberg (Copenhagen, Denmark)


Alexander Egeberg (Copenhagen, Denmark)

SAT 74.02 13:05 Clinical Presentation and Burden of Nail Psoriasis

Julia-Tatjana Maul (Zürich, Switzerland)

SAT 74.03 13:20 Deciphering the role of Nail Psoriasis in Psoriatic Disease

Progression

Frank Behrens (Frankfurt am Main, Germany)

SAT 74.04 13:35 Treatment of Nail Psoriasis: Choosing the Right Biologic


SAT 74.05 13:50 Q&A session



Unlocking the potential of immuno-oncology in advanced basal cell

carcinoma

13:00 - 14:00 Room: 2

Chair: Dirk Schadendorf (Essen, Germany)

SAT 75.01 13:00 Welcome and opening remarks

• Introductions

• History of immunotherapy in NMSC

Dirk Schadendorf (Essen, Germany)

SAT 75.02 13:05 Current treatment landscape in advanced BCC

Salvador Martin-Algarra (Pamplona, Spain)

SAT 75.03 13:20 Treatment paradigm and emerging approaches in advanced BCC

Dirk Schadendorf (Essen, Germany)

SAT 75.04 13:35 Clinical implication of emerging Immunotherapy for advanced BCC

Christoph Hoeller (Vienna, Austria)

SAT 75.05 13:50 Ask the faculty and concluding remarks


26



SATELLITE SYMPOSIA

SAT 76 AbbVie (HCP only)

Discovering tomorrow's treatment advances in Dermatology

13:00 - 14:00 Room: 3

Chair: Kilian Eyerich (Stockholm, Sweden)


Kilian Eyerich (Stockholm, Sweden)

SAT 76.02 13:15 Innovation in Dermatology: The journey so far…


SAT 76.03 13:20 Innovation in Dermatology: How did we get here?

Bradford McRae (Worcester, United States)

SAT 76.04 13:35 Innovation in Dermatology: What next!

Heath Guay (Worcester, United States)




UCB (HCP only)

Challenges and Opportunities in the Management of Psoriasis: The

Evolving Treatment Landscape

13:00 - 14:00 Room: 4

Chair: Richard Warren (Manchester, United Kingdom)

SAT 77.01 13:00 Welcome and Introductions

Richard Warren (Manchester, United Kingdom)

SAT 77.02 13:02 Challenges in the Optimization of Care of Patients With Psoriasis

Mark Lebwohl (New York, United States)

SAT 77.03 13:18 Impact of Psoriasis on Patients

Caitriona Ryan (Dublin, Ireland)

SAT 77.04 13:34 Biologic Therapies for Moderate to Severe Psoriasis


SAT 77.05 13:50 Panel Discussion


27



SATELLITE SYMPOSIA

SAT 78 Pfizer (HCP only)

How can we address varying patient needs in Atopic Dermatitis:

learnings from systemic JAK Inhibitors’ clinical trial outcomes.

13:00 - 14:00 Room: 5

Chair: Andreas Wollenberg (Munich, Germany)

SAT 78.01 13:00 Welcome and Review of AD, current treatment guidelines and the

JAK/STAT pathway in AD

Andreas Wollenberg (Munich, Germany)

SAT 78.02 13:15 Clinical Profiles: Characterization of Systemic JAK inhibitors From

the Molecule to the Clinic

Mette Deleuran (Aarhus, Denmark)

SAT 78.03 13:35 Going Deeper: Trials Designed to Explore Practical Questions


SAT 78.04 13:55 Live Q&A

All - panel discussion

SAT 79 LEO Pharma (HCP only, no US participants)

A New Biologic Targeting IL-13 in The Age of Disruption in Atopic

Dermatitis

13:00 - 14:00 Room: 6

Chair: Kristian Reich (Hamburg, Germany)

SAT 79.01 13:00 A New Biologic Targeting IL-13 in The Age of Disruption in Atopic

Dermatitis

Kristian Reich (Hamburg, Germany)

Andreas Wollenberg (Munich, Germany)

Jacob Thyssen (Copenhagen, Denmark)

Marjolein Bruin-Weller (Utrecht, Netherlands)

Jonathan Silverberg (Washington, United States)

28



SATELLITE SYMPOSIA

SAT 80 Galderma (HCP only)

Personalising Acne: Consensus of Experts to optimise acne

management

13:00 - 14:00 Room: 7

Chair: Alison Layton (Harrogate, United Kingdom)

SAT 80.01 13:00 Welcome


SAT 80.02 13:05 Highlights on current unmet needs in acne care


SAT 80.03 13:15 Improving future acne care through a structured expert consensus

Linda Stein Gold (Michigan, United States)

SAT 80.04 13:25 Personalised Acne Care Pathway: A practical solution for

longitudinal management


SAT 80.05 13:35 Live Q&A

All - panel discussion



SAT 82 Bristol Myers Squibb (HCP only, no industry participants)

Oral Therapies: Their Profiles and Roles in the Psoriasis Treatment

Landscape Bristol

13:00 - 14:00 Room: 9

Chair: Wolf Henning Boehncke (Geneva, Switzerland)

SAT 82.01 13:00 Unmet Needs in Psoriasis

Curdin Conrad (Geneva, Switzerland)

SAT 82.02 13:20 Mechanisms of Action for Oral Agents

Wolf Henning Boehncke (Geneva, Switzerland)

SAT 82.03 13:40 Clinical Data for Oral Agents in Psoriasis

Bruce Strober (Southington, United States)

29



SATELLITE SYMPOSIA

SAT 83 Developed by Medthority. Supported by educational sponsorship

from Novartis (HCP only)

Biologic heroes: Are you keeping up with the rapidly evolving

treatment landscape for paediatric psoriasis?

18:00 - 19:00 Room: 2

Chair: Amy Paller (Chicago, IL, United States)


Amy Paller (Chicago, IL, United States)

SAT 83.02 18:05 How are new treatments addressing the unmet needs in paediatric

psoriasis?

Amy Paller (Chicago, IL, United States)

SAT 83.03 18:20 Differentiating between the emerging approved biologic

treatments for paediatric psoriasis


SAT 83.04 18:35 Achieving long-term clearance in paediatric psoriasis

Marieke Seyger (Nijmegen, Netherlands)

SAT 83.05 18:50 Live Q&A and Panel Discussion



Are we experiencing a revolution in AD management?

18:00 - 19:30 Room: 3

Chair: Melinda Gooderham (Peterborough, Canada)


Melinda Gooderham (Peterborough, Canada)

SAT 84.02 18:05 Unmet needs in AD: where are we today?


SAT 84.03 18:35 Breaking boundaries in AD management


SAT 84.04 18:55 New frontiers in AD treatment

Jonathan Silverberg (Washington DC, United States)

SAT 84.05 19:25 Summary and conclusions


30



SATELLITE SYMPOSIA

SAT 85 Sanofi Genzyme (HCP only)

Taking the Long View on Disease Control in Atopic Dermatitis

18:00 - 19:30 Room: 4

Chair: Thomas Bieber (Bonn, Germany)



SAT 85.02 18:03 Long-term Disease Control in Atopic Dermatitis


SAT 85.03 18:27 Real-world Perspectives on Long-term Biologic Therapy for Atopic

Dermatitis


SAT 85.04 18:51 The Evolving Therapeutic Landscape for Patients with Moderate-to-

Severe Atopic Dermatitis




SAT 86 Med Learning Group on behalf of Regeneron Pharmaceuticals, Inc

and Sanofi Genzyme (Open to all)

A Whiteboard View of Systemic Management of Advanced Basal

Cell Carcinoma: Going Beyond Aberrant Pathway Signaling to

Activate the Immune Response

18:00 - 19:30 Room: 5

Chair: Aimilios Lallas (Thessaloniki, Greece)

SAT 86.01 18:00 Pathogenesis of Advanced Basal Cell Skin Cancer

Aimilios Lallas (Thessaloniki, Greece)

SAT 86.02 18:20 Epidemiology of Basal Cell Carcinoma

Aimilios Lallas (Thessaloniki, Greece)

SAT 86.03 18:45 NCCN Practice Guidelines in Locally Advanced/Metastatic Disease

Anokhi Jambusaria-Pahlajani (Austin, United States)

SAT 86.04 19:05 Emerging Immune Checkpoint Inhibition for Systemic Disease

Anokhi Jambusaria-Pahlajani (Austin, United States)

SAT 86.05 19:15 Conclusions/Question-and Answers


31



SATELLITE SYMPOSIA


The dermatologist’s guide to the clearance of the skin

18:00 - 19:15 Room: 6

Chairs: Kilian Eyerich (Stockholm, Sweden)

Melinda Gooderham (Peterborough, ON, Canada)

Brian Kirby (Dublin, Ireland)



SAT 87.02 18:05 Don’t panic! New strategy for established treatment on the horizon


SAT 87.03 18:20 The answer to the ultimate question: long-term clinical and registry

data


SAT 87.04 18:35 And another thing… looking beyond the skin in psoriasis patients

Melinda Gooderham (Peterborough, ON, Canada)

SAT 87.05 18:50 Panel discussion and Q&A


SAT 87.06 19:10 So long, and thanks for all the questions



Prurigo Nodularis: From Patient to Pathway

18:00 - 19:30 Room: 7

Chair: Gil Yosipovitch (Miami, United States)

SAT 88.01 18:00 Welcome and introduction by Chairperson

Gil Yosipovitch (Miami, United States)

SAT 88.02 18:03 The Multi-Dimensional Impact of Prurigo Nodularis


SAT 88.03 18:17 Illuminating the Role of IL-31: The Neuro-Immune Cytokine

Martin Steinhoff (Doha, Qatar)

SAT 88.04 18:31 Investigational Product - Nemolizumab: The Next Generation

Therapy in Phase 3 for PN

Sonja Ständer (Münster, Germany)

SAT 88.05 18:45 Live Q&A With All Speakers and Symposium Closing Address


Martin Steinhoff (Doha, Qatar)

Sonja Ständer (Münster, Germany)

32



SATELLITE SYMPOSIA


A novel approach in the management of patients with Actinic

Keratosis

18:00 - 19:30 Room: 8

Chair: Rolf-Markus Szeimies (Recklinghausen, Germany)


Rolf-Markus Szeimies (Recklinghausen, Germany)

SAT 89.02 18:05 Clinical data landscape in Actinic Keratosis


SAT 89.03 18:20 MoA of current treatments in Actinic Keratosis

Yolanda Gilaberte (Zaragoza, Spain)

SAT 89.04 18:35 Clinical cases discussion

Edward Lain (Austin, United States)

SAT 89.05 18:50 Q&A


33



INDUSTRY HUB

HUB 1.03 L’Oréal Paris (Open to all)

NEW TRENDS IN HYALURONIC ACID: The Dermatologist’s gold

standard in fillers becomes the new must-have for moisture and

plump in cosmetic routines

11:15-12:00 Room: HUB 1

Chair: Sabine Zenker (Munich, Germany)

HUB 1.03.01 11:15 The science of Hyaluronic Acid: mechanism of action in the skin

Sabine Zenker (Munich, Germany)

HUB 1.03.02 11:24 Hyaluronic Acid: what’s new in professional procedures:

microneedling, fractional lasers, healing

Maria Teresa Luverà (Livorno, Italy)

HUB 1.03.03 11:29 The place of Hyaluronic Acid in women cosmetic routines: clinical

cases

Cristina Eguren (Madrid, Spain)

HUB 1.03.04 11:34 The benefits that cosmetic Hyaluronic Acid can bring to our

younger patients

Ophelia Veraitch (London, United Kingdom)

HUB 1.03.05 11:39 Hyaluronic Acid, a pillar in anti-aging routines for all women

Dr Laurence Walon (Brussels, Belgium)

HUB 1.03.06 11:44 Myths & Truths about Hyaluronic Acid

Christian Tran (Paris, France)

HUB 1.03.07 11:49 Clinical evaluation of plump and its evolution with age: A new

method and standardized atlas

Frédéric Flament (Paris, France)

HUB 1.03.08 11:54 Serum formulation with 1.5% of pure HA: Clinical studies and

results after 1 week, 4 weeks, 6 weeks

Elisabeth Bouhadana (Paris, France)

HUB 1.04 Amgen (HCP only)

Unveiling the patient with moderate plaque psoriasis patient:

Expanding existing knowledge with real‑world data

12:15-13:00 Room: HUB 1

Chair: Paolo Gisondi (Verona, Italy)

HUB 1.04.01 12:15 Unveiling the patient with moderate plaque psoriasis: Expanding

existing knowledge with real‑world data

Paolo Gisondi (Verona, Italy)

HUB 1.04.02 12:45 Audience Q&A


34



INDUSTRY HUB

HUB 1.05 Sofwave (Open to all)

Sofwave, The Newest in Ultrasound Technology. A review of

clinical studies, technology and a demonstration. Synchronous

Ultrasound Parallel Beam Technology SUPERB for skin tightening.

14:00-14:45 Room: HUB 1

Chair: Michael Gold (Nashville, United States)

HUB 1.05.01 14:00 Sofwave, The Newest in Ultrasound Technology. A review of

clinical studies, technology and a demonstration. Synchronous

Ultrasound Parallel Beam Technology SUPERB for skin tightening.

Michael Gold (Nashville, United States)

HUB 1.06 L'Oréal - La Roche-Posay (Open to all)

Managing skin side effects from cancer treatments: where do we

stand?

15:00-15:45 Room: HUB 1

Chairs: Brigitte Dréno (Nantes, France)

Mario Lacouture (NYC, United States)

HUB 1.06.01 15:00 Prophylaxis and management of skin toxicities by the

dermatologist


HUB 1.06.02 15:10 How can supportive care improve quality of life

Mario Lacouture (NYC, United States)

HUB 1.06.03 15:40 Q&A


35



INDUSTRY HUB

HUB 1.07 CeraVe (Open to all)

Restoring Lipid Structure Organization Leads to Improved Patient

Outcomes in Dry, Eczema-Prone Skin

16:00-16:45 Room: HUB 1

Chair: Michael J. Cork (Hope Valley, United Kingdom)

HUB 1.07.01 16:00 Restoring Lipid Structure Organization Leads to Improved Patient

Outcomes in Dry, Eczema-Prone Skin

Michael J. Cork (Hope Valley, United Kingdom)

HUB 1.07.02 16:35 Live Q & A

Michael J. Cork (Hope Valley, United Kingdom)

HUB 2.01 Galderma (Open to all)

The many faces of Maskne – a new skin burden / an upcoming

disease

09:00-09:45 Room: HUB 2

Chair: Markus Reinholz (Munich, Germany)

HUB 2.01.01 09:00 Introduction

Markus Reinholz (Munich, Germany)

HUB 2.01.02 09:02 Polling Part 1


HUB 2.01.03 09:04 Maskne an upcoming disease


HUB 2.01.04 09:14 Q&A Part 1



Anne-Charlotte Kuna (Munich, Germany)

HUB 2.01.06 09:19 Maskne the Munich experience


HUB 2.01.07 09:27 Q&A Part 2




HUB 2.01.09 09:32 Therapeutic Options for Maskne


HUB 2.01.10 09:42 Q&A Part 3 & Conclusion


36



INDUSTRY HUB

HUB 2.02 PIERRE FABRE DERMATOLOGIE (HCP only)

Beyond the results of treatments, look for actinic keratosis severity

10:00-10:45 Room: HUB 2

HUB 2.02.01 10:00 Welcome and introduction

Alain Delarue (Lavaur, France)

HUB 2.02.02 10:03 What are AK patients’ expectations when treating a field

cancerization?

Maria Concetta Fargnoli (L'Aquila, Italy)

HUB 2.02.03 10:13 Network meta-analysis: a tool for finding a way in the jungle of

treatments for actinic keratosis

Khaled Ezzedine (Bordeaux, France)

HUB 2.02.04 10:25 When treating a field cancerization, consider AK severity

Eggert Stockfleth (Bochum, Germany)

HUB 2.02.05 10:40 Questions-Answers

Alain Delarue (Lavaur, France)

Maria Concetta Fargnoli (L'Aquila, Italy)

Khaled Ezzedine (Bordeaux, France)


HUB 2.03 LEO Pharma (HCP only)

Navigating through an era of targeted therapies for atopic

dermatitis

11:15:12:00 Room: HUB 2



HUB 2.03.02 11:20 Where do we stand on the road to targeted therapies for atopic

dermatitis?


HUB 2.03.03 11:30 Tailored treatments based on patient expectations


HUB 2.03.04 11:40 Making the therapeutic choice



HUB 2.03.05 11:50 Q&A

Speakers & audience

37



INDUSTRY HUB

HUB 2.04 UCB (HCP only)

Nominations are in: The psoriasis pathogenesis awards

12:15-13:00 Room: HUB 2

Chair: Wolf-Henning Boehncke (Geneva Switzerland)

HUB 2.04.01 12:15 Welcome and Introduction

Wolf-Henning Boehncke (Geneva, Switzerland)

HUB 2.04.02 12:18 A crucial contribution: The IL-23/IL-17 axis in psoriasis


HUB 2.04.03 12:30 A clear focus: Targeting the key drivers of disease

Lluís Puig (Barcelona, Spain)

HUB 2.04.04 12:40 A long view: How will clear skin benefit patients?

Menno de Rie (Amsterdam, The Netherlands)

HUB 2.04.05 12:49 Panel discussion and questions from the audience

Wolf-Henning Boehncke (Geneva Switzerland) Lluís Puig (Barcelona, Spain)

Menno de Rie (Amsterdam, The Netherlands)

HUB 2.04.06 12:59 Conclusions and meeting closes


38



INDUSTRY HUB

HUB 2.05 Almirall (HCP only)

Advancing the standard of care in AD: can we be more specific?

14:00-14:45 Room: HUB 2

Chair: Jacob Thyssen (Copenhagen, Denmark)

HUB 2.05.01 14:00 Welcome and introductions


HUB 2.05.02 14:01 Burden of atopic dermatitis for patients – really understanding

patient unmet needs


HUB 2.05.03 14:05 Pathophisiology of the disease and potential therapeutical targets

Stephan Weidinger (Kiel, Germany).

HUB 2.05.04 14:08 Strategy of blocking IL4/IL13 – first biologic available and big

advancement, but there are still unmet needs



HUB 2.05.05 14:18 Strategy of blocking IL13 alone– might it be enough to control

atopic dermatitis?



HUB 2.05.06 14:30 Questions and answers - discussion



39



INDUSTRY HUB

HUB 2.06 Janssen (HCP only)

Remember to forget me: the disease modifying potential of

targeting tissue-resident memory cells in psoriasis

15:00-15:45 Room: HUB 2

Chair: James Krueger (New York, United States)


Tiago R. Matos (Amsterdam, Netherlands)

HUB 2.06.02 15:05 Looking behind the scenes – disease memory in psoriasis

James Krueger (New York, United States)

HUB 2.06.03 15:20 Moving towards remission – long-term treatment in psoriasis


HUB 2.06.04 15:35 Q&A



HUB 2.06.05 15:40 Conclusion and close



The XX-factor: Does a patient’s sex matter in psoriasis?

16:00-16:45 Room: HUB 2

Chair: Cæcilie Bachdal Johansen (Copenhagen, Denmark)

HUB 2.07.01 16:00 Welcome, housekeeping and introduction

Cæcilie Bachdal Johansen (Copenhagen, Denmark)

HUB 2.07.02 16:11 Perspectives in favour of considering patient sex

Nina Magnolo (Münster, Germany)

HUB 2.07.03 16:23 Teaching perspectives in areas not considering patient sex

Álvaro González-Cantero (Madrid, Spain)

HUB 2.07.04 16:31 Live Q&A and polling


HUB 2.07.05 16:43 Closing remarks

Cæcilie Bachdal Johansen (Copenhagen, Denmark)

40



SATELLITE SYMPOSIA

SAT 95 Galderma (Open to all)

Advancing Sensitive Skin: Diagnosis, Morphological Traits and

Epidemiology

08:30-09:30 Room: 1

Chair: Giovanni Pellacani (Rome, Italy)

SAT 95.01 08:30 Diagnosis of sensitive skin - is there an ideal tool?

Laurent Misery (Brest, France)

SAT 95.02 08:45 Discovery of morphological traits to differentiate sensitive skin

from non-sensitive skin

Giovanni Pellacani (Rome, Italy)

SAT 95.03 09:00 Proposal for Cut-off Scores for Sensitive Skin on Sensitive Scale-10

Emilie Brenaut (Brest, France)

SAT 95.04 09:10 Profiling of sensitive skin using clinical data, Real life data meta-

analysis

Gwendoline Baruchet (Vevey, Switzerland)

SAT 95.05 09:20 Live Q&A

Giovanni Pellacani (Rome, Italy)

SAT 108 Novartis (HCP only)

Targeting complete CSU control: current state of the art and future

perspectives

13:00-14:00 Room: 1

Chair: Ana Maria Giménez-Arnau (Barcelona, Spain)

SAT 108.01 13:00 Welcome and introductions

Ana Maria Giménez-Arnau (Barcelona, Spain)

SAT 108.02 13:05 The patient journey in CSU: The challenges we face


SAT 108.03 13:15 Optimizing patient outcomes in CSU: Could new biologics help

achieve this?

Romi Saini (Baltimore, United States)

SAT 108.04 13:30 Exploring novel pathways in the journey to complete CSU control

John Reed (Oxford, United Kingdom)

SAT 108.05 13:45 Live Q&A


SAT 108.06 13:55 Summary and closing remarks


41



SATELLITE SYMPOSIA


Demystifying JAK inhibitors: what do I need to know?

13:00-14:00 Room: 2

Chair: Alan Irvine (Dublin, Ireland)



SAT 109.02 13:05 Why JAK inhibitors for atopic dermatitis


SAT 109.03 13:20 Who can benefit from JAK inhibitors


SAT 109.04 13:35 How do I use JAK inhibitors?


SAT 109.05 13:55 Summary and Conclusions



Planning For The Future: It’s Time For Long-Term Control In Atopic

Dermatitis

13:00-14:00 Room: 3

Chairs: Melinda Gooderham (Peterborough, Canada)

Michael Cork (Sheffield, United Kingdom)


Vivienne Parry (Oxfordshire, United Kingdom)

SAT 110.02 13:05 Exploring the burden of AD in pediatric and adult patients [video]


SAT 110.03 13:10 Burden of AD in pediatric and adult patients


SAT 110.04 13:20 Moderated discussion


SAT 110.05 13:30 Treatment selection for patients with AD


SAT 110.06 13:40 Moderated discussion


SAT 110.07 13:50 Q&A with audience


42



SATELLITE SYMPOSIA

SAT 111 UCB (HCP only)

Awards night! New advances in treating psoriasis

13:00-14:00 Room: 4


SAT 111.01 13:00 Welcome and Introduction


SAT 111.02 13:03 Overall picture: Targeting key drivers of psoriasis


SAT 111.03 13:18 Lasting contribution: Achieving a rapid response that lasts

Diamant Thaçi (Lübeck, Germany)

SAT 111.04 13:33 Meaningful improvement: Improving quality of life for patients

with psoriasis


SAT 111.05 13:48 Panel discussion and questions from the audience




SAT 111.06 13:58 Conclusions and meeting close


SAT 112 Pfizer (HCP only)

Navigating the new world of dermatology

13:00-14:00 Room: 5


Dr Zakiya Rice (Atlanta, United States)

SAT 112.02 13:05 Decoding the updated road map: from patient to treatment - Part I:

Immunological concepts in dermatology

Ali Jabbari (lowa City, United States)

SAT 112.03 13:15 Decoding the updated road map: from patient to treatment - Part

II: Matching treatment to disease


SAT 112.04 13:30 Plotting your patient’s course with practical decision making


SAT 112.05 13:55 A medical education programme for dermatology

Dr Zakiya Rice (Atlanta, United States)

43



SATELLITE SYMPOSIA


Moderate to Severe Atopic Dermatitis – a disease of the skin and

beyond

13:00-14:00 Room: 6

Chair: Diamant Thaçi (Lübeck, Germany)

SAT 113.01 13:00 Welcome and Introduction by the Chair


SAT 113.02 13:02 Atopic Dermatitis burden beyond the skin


SAT 113.03 13:16 IL-31: the central neuro-immune cytokine in AD

Bernhard Homey (Düsseldorf, Germany)

SAT 113.04 13:30 Blocking IL-31 signalling in AD – the nemolizumab emerging clinical

data


SAT 113.05 13:44 Live panel discussion and Q&A

All Faculty


Are you wasting your time getting to PASI100?

Come and listen to the brain fight with the skin!

13:00-14:00 Room: 7

Chair: Stefano Piaserico (Padova, Italy)


Stefano Piaserico (Padova, Italy)

SAT 114.02 13.05 Round 1: The dermatologist vs the behavioral scientist - who is

better at managing our patients?


Jordi Quoidbach (Barcelona, Spain)

SAT 114.03 13:35 How can we apply patient wellbeing to psoriasis? Introducing the

POSITIVE study: Patient-reported wellbeing using tildrakizumab in

a live setting

Ulrich Mrowietz (Kiel, Germany)

SAT 114.04 13:55 Closing


44



SATELLITE SYMPOSIA

SAT 115 LABORATOIRES DERMATOLOGIQUES AVENE (Open to all)

“Light and shadows of blue light and sunscreens - a dermatological,

environmental and patients perspective”

13:00-14:00 Room: 8

Chair: Eggert Stockfleth (Bochum, Germany)


Ariadna Ortiz Brugués (Lavaur, France)

SAT 115.02 13:03 Looking at blue light: new perspectives in sunscreens


SAT 115.03 13:23 Fate of UV filters in the marine environment: from portioning to

ecotoxicity

Philippe Lebaron (Paris, France)

SAT 115.04 13:38 Photoprotection and self skin examination to improve melanoma

survival

Enrique Barba (Barcelona, Spain)

SAT 115.05 13:48 Discussion




Ariadna Ortiz Brugués (Lavaur, France)

SAT 115.06 13:55 Q & A




45



SATELLITE SYMPOSIA


Psoriasis management: Reducing the long-term impact of psoriasis

“Commit to clear: changing lives for the long term”

18:00-19:30 Room: 2




SAT 117.02 18:05 Why commit to clear?


SAT 117.03 18:20 Best chance for clear


SAT 117.04 18:40 A clear difference


SAT 117.05 18:55 Changing lives for the long term






46



SATELLITE SYMPOSIA


Targeting Better Disease Control in Pediatric Patients with Atopic

Dermatitis

18:00-19:30 Room: 3

Chair: Amy Paller (Chicago, United States)



SAT 118.02 18:05 Aspects of Disease Burden in Pediatric Patients with Atopic

Dermatitis

Ulrike Blume-Peytavi (Berlin, Germany)

SAT 118.03 18:29 Managing Atopic Dermatitis in Pediatric Patients


SAT 118.04 18:53 Expanding Treatment Options for the Pediatric Patient

Lawrence Eichenfield (San Diego, United States)




The art of joint forces: crafting PsA care for dermatologists

18:00-19:15 Room: 4

Chairs: Alexander Egeberg (Copenhagen, Denmark)

Laura Savage (Leeds, United Kingdom)

Joseph Merola (Boston, United States)



SAT 119.02 18:05 Dermatologists’ toolbox for the early detection of PsA


SAT 119.03 18:20 The nuts and bolts of PsA therapy


SAT 119.04 18:35 Carving the road to lasting peace: designing effective PsA

treatment in daily practice

Joseph Merola (Boston, United States)

SAT 119.05 18:50 Painting harmony: tips and pitfalls from combined clinics


SAT 119.06 19:05 Q&A and closing


47



SATELLITE SYMPOSIA


New insights on Papulopustular Rosacea and Systemic Therapy

18:00-19:30 Room: 5

Chair: James Q. Del Rosso (Las Vegas, United States)

SAT 120.01 18:00 Welcome and Introduction

James Q. Del Rosso (Las Vegas, United States)

SAT 120.02 18:05 Papulopustular Rosacea: who are our patients

Hilary E. Baldwin (New Jersey, United States)

SAT 120.03 18:15 The systemic treatment spectrum: current landscape


SAT 120.04 18:30 Getting the best out of rosacea treatment: a need for a new expert

consensus?

Martin Schaller (Tübingen, Germany)

SAT 120.05 18:40 Live panel discussion and Q&A

All faculty



SAT 121 Boehringer Ingelheim International GmbH (HCP only)

Generalized Pustular Psoriasis: Mind the GaPP

18:00-19:30 Room: 6

Chair: Diamant Thaçi (Luebeck, Germany)

SAT 121.01 18:00 Welcome & Introduction


SAT 121.02 18:05 United: Bridging the GaPP

Sicily Mburu (Bromma, Sweden)

SAT 121.03 18:15 Exploring the GaPP in Everyday Practice

Melinda Gooderham (Peterborough, ON,Canada)

SAT 121.04 18:35 GaPPs in the 40-year Therapeutic Path Trudge

Luis Puig (Barcelona, Spain)

SAT 121.05 18:50 Closing the GaPP: Evolving the Treatment of GPP

David Burden (Glasgow, United Kingdom)

SAT 121.06 19:10 Panel discussion


48



INDUSTRY HUB

HUB 1.08 L'Oréal - La Roche-Posay (Open to all)

Atopic dermatitis: new technology to act fast during flare ups at all

ages

09:00-09:45 Room: HUB 1

Chair: Bernhard Homey (Düsseldorf, Germany)

HUB 1.08.01 09:00 Atopic dermatitis and microbiome: where do we stand?

Bernhard Homey (Düsseldorf, Germany)

HUB 1.08.02 09:10 Introducing Endobioma: inspired by the phage technology

Anne-Laure Demessant (Paris, France)

HUB 1.08.03 09:40 Q&A

Anne-Laure Demessant (Paris, France)

HUB 1.09 siHealth (HCP only)

Experiences of Actinic Keratosis (AK) daylight PDT treatment

supported by the SmartPDT digital system

10:00-10:45 Room: HUB 1

Chair: Emilio Simeone (Oxford, United Kingdom)


Emilio Simeone (Oxford, United Kingdom)

HUB 1.09.02 10:10 Daylight PDT AK lesion precision dosimetry : the new dPDT

challenge

Ewan Eadie (Dundee, United Kingdom)

HUB 1.09.03 10:25 SmartPDT: real-word evidences of a digitally supported home self-

administered dPDT of AK

Yolanda Gilaberte (Zaragoza, Spain)

HUB 1.09.04 10:40 Q&A Session

Emilio Simeone (Oxford, United Kingdom)

49



INDUSTRY HUB

HUB 1.11 Vichy Laboratoires (Open to all)

Dandruff and seborrheic dermatitis: from the microbiome science

to clinical evidence

12:15-13:00 Room: HUB 1

Chair: Sergio Vaño-Galván (Madrid, Spain)

HUB 1.11.01 12:15 Dandruff and seborrheic dermatitis: the central role of scalp

microbiome

Sergio Vaño-Galván (Madrid, Spain)

HUB 1.11.02 12:30 Dercos ds solution proven efficacy: from microbiome impact to

clinical study results

Eugenia Capetta (Buenos Aires, Argentina)

HUB 1.11.03 12:45 Q&A

Sergio Vaño-Galván (Madrid, Spain)

HUB 1.12 Pfizer (HCP only)

Dermatology and diversity: 3 short talks about the future we all

want to create

14:00-14:45 Room: HUB 1

Chair: Seemal Desai (Dallas, United States)

HUB 1.12.01 14:00 Opening and intro to our equity platform

Seemal Desai (Dallas, United States)

HUB 1.12.02 14:10 The significance of skin: Some cultural context

Nina Jablonski (Philadelphia, United States)

HUB 1.12.03 14:20 Diversity: a dermatological perspective


HUB 1.12.04 14:30 In my own skin

Natalie Ambersley (Hornchurch, United Kingdom)

HUB 1.12.05 14:40 Closing: wrap up and invitation to visit the platform


50



INDUSTRY HUB

HUB 1.13 CeraVe (Open to all)

Clinical Solutions for Chronic Drug-Induced Xerosis in Elderly

Patients

15:00-15:45 Room: HUB 1

Chair: Federica Filippi (Bologna, Italy)

HUB 1.13.01 15:00 Clinical Solutions for Chronic Drug-Induced Xerosis in Elderly

Patients

Federica Filippi (Bologna, Italy)

HUB 1.13.02 15:35 Live Q & A

Federica Filippi (Bologna, Italy)

51



INDUSTRY HUB

HUB 2.08 Galderma (Open to all)

Onychomycosis Update – Novel findings: Prevalence, epidemiology

and topical Therapy

09:00-09:45 Room: HUB 2

Chair: Dieter Reinel (Hamburg, Germany)


Dieter Reinel (Hamburg, Germany)

HUB 2.08.02 09.02 Onychomycosis Update – Novel findings: Prevalence, epidemiology

and topical Therapy


HUB 2.08.03 09:40 Q&A


Schafiq Nabhani (Düsseldorf, Germany)


Explore the latest science and data of plaque psoriasis flare control

with Cal/BD foam

11:15-12:00 Room: HUB 2

Chair: Anthony Bewley (London, United Kingdom)


Presenter

HUB 2.10.02 11:20 Key factors in treatment success in psoriasis with topical therapy

Ahmad Jalili (Buochs, Switzerland)

HUB 2.10.03 11:25 The science of flare control with Cal/BD foam

Presenter

HUB 2.10.04 11:35 Clinical update: QoL from the 4-week, open-label phase of PSO-

LONG


HUB 2.10.05 11:40 Clinical update: Cal/BD foam: Impact in real-world clinical settings.


HUB 2.10.06 11:50 Discussion: Practical implications for the topical treatment of

patients with mild-to-moderate psoriasis



52



INDUSTRY HUB

HUB 2.11 Janssen (HCP only)

The road to safety: a clinical dialogue on the safety of biologics in

psoriasis

12:15-13:00 Room: HUB 2

Chairs: Kenneth Gordon (Milwaukee, United States)

Elke de Jong (Nijmegen, Netherlands)


Kenneth Gordon (Milwaukee, United States)

HUB 2.11.02 12:20 Bringing peace to a body at war – IL-23 and IL-17 inhibitors, are

they safe? A dialogue on clinical trial and real-world safety data



HUB 2.11.03 12:30 Q&A



HUB 2.11.04 12:35 A Balancing Act – immunosuppression and immune defence in

psoriasis and psoriatic arthritis



HUB 2.11.05 12:45 Q&A



HUB 2.11.06 12:55 Conclusion and Close


53



INDUSTRY HUB


Long-term maintenance treatment of plaque psoriasis with Cal/BD

foam. A new approach in topical therapy

14:00-14:45 Room: HUB 2

Chair: Linda Stein Gold (Detroit, United States)


Presenter

HUB 2.12.02 14:05 Why is a chronic condition like psoriasis often managed reactively

and what challenges do patients face with this treatment

approach? What is the expert view on using topical treatments in

psoriasis over the long-term?

Presenter

HUB 2.12.03 14:10 Exploring data and benefits of long-term, proactive management of psoriasis over 52-weeks with Cal/BD foam

Presenter

HUB 2.12.04 14:20 Proactive management with Cal/BD foam in PSO-LONG: Efficacy

and safety update.

Michael Sticherling (Erlangen, Germany)

HUB 2.12.05 14:30 Health-related quality of life improvements with long-term,

proactive management using Cal/BD foam

Linda Stein Gold (Detroit, United States)

HUB 2.12.06 14:35 Round table discussion: What are the practical implications for

long-term, proactive management of psoriasis with Cal/BD foam?

Michael Sticherling (Erlangen, Germany)

Linda Stein Gold (Detroit, United States)

54



INDUSTRY HUB

HUB 2.13 LEO Pharma (HCP Only)

Adult Female Acne: Case Studies on Current Challenges and

Lessons Learned

15:00-15:45 Room: HUB 2

Chair: Alison Layton (Harrogate, United Kingdom)

HUB 2.13.01 15:00 Welcome


HUB 2.13.02 15:02 Introduction to clinical characteristics of adult female acne

Ediléia Bagatin (São Paulo, Brazil)

HUB 2.13.03 15:10 Adult female acne: Case studies from UK


HUB 2.13.04 15:20 Adult female acne: Case studies from Brazil


HUB 2.13.05 15:30 LIVE Q&A




Don’t delay: Support women with psoriasis on their journey to

motherhood

16:00-16:45 Room: HUB 2

Chair: Aikaterini Patsatsi (Thessaloniki, Greece)

HUB 2.14.01 16:00 Welcome, housekeeping and introductions

Aikaterini Patsatsi (Thessaloniki, Greece)

HUB 2.14.02 16:02 Management of women with psoriasis: Shared decision making

Annunziata Dattola (Rome, Italy)

HUB 2.14.03 16:10 Management of women with psoriasis: a holistic view


HUB 2.14.04 16:20 Discussion: The MDT perspective in treating women with psoriasis


HUB 2.14.05 16:34 Live Q&A with audience


HUB 2.14.06 16:43 Closing remarks


55



SATELLITE SYMPOSIA

SAT 151 Boehringer Ingelheim International GmbH (HCP only)

Don’t Judge a Book by Its Cover: Uncovering the Role of

Autoinflammation in Skin Disease

18:00-19:30 Room: 2

Chair: Georg Stingl (Vienna, Austria)

SAT 151.01 18:00 IL-36: A Novel Pathway in Inflammation

Georg Stingl (Vienna, Austria)

SAT 151.02 18:10 A New-trophilic Chapter in Hidradenitis Suppurativa

Errol Prens (Rotterdam, Netherlands)

SAT 151.03 18:30 Inflammatory Pathways and Patient Impact in Atopic Dermatitis

Patrick Brunner (New York, United States)

SAT 151.04 18:50 Exposing a Major Character in Pustular Forms of Psoriasis

Hervé Bachelez (Paris, France)

SAT 151.05 19:05 Wrapping Up the Loose Ends: IL-36 Inhibition in Inflammatory Skin

Diseases

Robert Bissonnette (Montreal, Canada)

SAT 151.06 19:20 Q&A Panel


56



INDUSTRY HUB


Let the celebrations begin: Giving patients the opportunity to take

control of their psoriasis

10:00-10:45 Room: HUB 2

Chair: Sandy McBride (London, United Kingdom)


Sandy McBride (London, United Kingdom)

HUB 2.16.02 10:03 Who’s celebrating? Introducing the patient

Andreas Pinter (Frankfurt, Germany)

HUB 2.16.03 10:13 Celebrating with style: Treat to target


HUB 2.16.04 10:23 Celebrating improvements: Aiming for clear skin


HUB 2.16.05 10:33 Panel discussion and questions from the audience


Andreas Pinter (Frankfurt, Germany)


HUB 2.16.06 10:43 Conclusions and meeting close


HUB 2.18 Galderma (HCP only)

Artificial daylight photodynamic therapy: Advancing actinic

keratosis treatment

12:15-13:00 Room: HUB 2

Chair: Rolf-Markus Szeimies (Recklinghausen, Germany)



HUB 2.18.02 12:20 Can daylight photodynamic therapy be performed indoors?

Serge Mordon (Ascain, France)

HUB 2.18.03 12:30 What is the clinical evidence of artificial daylight photodynamic

therapy for actinic keratosis?


HUB 2.18.04 12:40 Practical demonstration video


HUB 2.18.05 12:43 Live panel discussion and Q&A

All faculty

HUB 2.18.06 12:58 Conclusion


57



INDUSTRY HUB


Topical Antimicrobials: Data, Guidelines, and Real-Life Practice

14:00-14:45 Room: HUB 2

Chair: Diamant Thaçi (Lübeck, Germany)



HUB 2.19.0 14:05 How topical antibiotics work and data from clinical trials


HUB 2.19.0 14:15 An overview of topical antifungal treatments and their efficacy

Stefano Veraldi (Milan, Italy)

HUB 2.19.0 14:25 Guidelines, reviews, and treatment considerations



HUB 2.19.0 14:35 Panel discussion and Q&A



industry session programmes

Documents